Antimicrobial Coatings Medical Devices Market in 2025

Hospital-acquired infections (HAIs) are one of the most quantifiable cost problems in modern healthcare, and antimicrobial coatings for medical devices are the primary engineering-level defence against them. The CDC estimates 722,000 HAIs occur in US hospitals annually, generating $28–33 billion in excess healthcare costs. Central-line-associated bloodstream infections (CLABSI) add roughly $63,000 per case; surgical site infections add $37,000. These figures give antimicrobial-coated devices a quantifiable economic case that few other medtech categories can match — and they are the reason this market has sustained a double-digit CAGR for a decade.

The global antimicrobial medical device coatings market was valued at approximately $2.98 billion in 2025, according to The Business Research Company (2026 market report). It is expected to reach $6.49 billion by 2031 at a compound annual growth rate of 13.2%, per The Insight Partners (May 2025). A broader definition encompassing the coated finished devices puts the addressable market at $12.4 billion by 2033. The CAGR on the narrower coating-services-and-materials view sits at 16.7% between 2025 and 2030 on some estimates, reflecting aggressive hospital procurement of coated catheters and implants post-pandemic as HAI rates climbed back toward pre-COVID baselines.

Dominant Coating Technologies and Application Segments

Silver-ion and silver nanoparticle coatings hold the largest share of the market, primarily because silver's broad-spectrum antimicrobial activity is well-documented and its safety profile (when properly dose-controlled) is accepted by the FDA and MHRA. Chlorhexidine-based coatings, polyhexamethylene biguanide (PHMB), and antibiotic-loaded matrices are the next tier. The most clinically sensitive segment — and the largest revenue category — is intravascular catheters, which account for roughly 40% of antimicrobial coating revenue. Orthopaedic implants (hip stems, tibial plates, external fixation pins) are the second major category, driven by the particularly severe consequences of periprosthetic joint infections (PJI), where revision surgery costs can exceed $100,000 per patient.

Three business models are used commercially. Technology licensors (Microban International, Sciessent LLC) develop the antimicrobial formulation and IP, then license it to OEM device manufacturers. Contract coaters (Hydromer Inc., Biocoat Inc.) apply coatings to client-supplied devices for a per-device or per-batch service fee. Integrated device makers (Covalon Technologies, BD's antimicrobial catheter line) manufacture and sell the finished coated device at retail. The business model you select determines your capital requirements, regulatory burden, and time to revenue — all of which must be mapped in your business plan before approaching investors or lenders.

Geography: Where Revenue Is Being Generated

North America is the largest regional market, driven by the size of the US hospital system, the established FDA pathway for coated devices, and aggressive hospital group purchasing organisation (GPO) procurement contracts. Europe is the second largest, with Germany, France, and the UK representing the bulk of demand. Asia-Pacific is the fastest-growing region, particularly China and India, where rapid expansion of surgical capacity and rising HAI awareness are pulling in coated catheter and implant products. Companies entering this market with a licensing model often find that targeting mid-tier OEMs in Southeast Asia generates early royalty income while the US pipeline matures through 510(k) review.

SBA Loans & SBIR Grants for Antimicrobial Coatings Startups

Antimicrobial coatings for medical devices sits at the intersection of two federal funding tracks that rarely overlap: SBA commercial lending (NAICS 325510 — Paint, Coating and Adhesive Manufacturing; or 339112 — Surgical and Medical Instrument Manufacturing) and NIH/DoD SBIR/STTR programmes specifically allocated to infection prevention technology.

SBA 7(a) Loans

SBA 7(a) loans fund working capital, equipment purchase, and facility fit-out up to $5 million at partially guaranteed rates. For an antimicrobial coatings company, eligible expenditures include ultrasonic spray or dip-coating equipment, clean-room build-out, and initial ISO 13485 implementation. SBA 7(a) approval rates for manufacturing-sector small businesses typically run 60–75% for borrowers with two or more years of operating history and a DSCR above 1.25. For a pre-revenue startup, an SBA Microloan (up to $50,000) or a local SBDC-backed CDFi loan is typically more accessible as a bridge before a 7(a) application.

NIH SBIR / STTR: The Primary Early-Stage Track

The NIH Small Business Innovation Research programme is structured specifically for R&D-intensive medical technology startups. Phase I awards fund feasibility: up to $314,363 (FY2025 standard budget), non-dilutive, and requiring only a 6-month performance period. The majority of antimicrobial coatings companies use a Phase I to fund biofilm challenge testing (ASTM E2562 or ISO 22196), biocompatibility profiling (ISO 10993 series), and pre-510(k) FDA engagement. Phase II awards extend proven concepts at up to $2,095,753 over 2 years — enough to cover an FDA 510(k) pre-submission meeting, the formal submission itself, and an initial clinical pilot at a partner hospital. SPARTHA Medical, a French bioactive coatings startup, received €3.8 million in equivalent grant and EIC funding by 2022, demonstrating that public non-dilutive capital can carry a coatings company to early licensing traction before any venture equity is required.

DoD SBIR and Rapid Innovation Fund

The US Department of Defense runs parallel SBIR funding specifically for infection prevention in military medical facilities and field hospitals. Antimicrobial coatings for trauma implants, external fixators, and field-sterilisable instruments are directly funded through Army Medical Research Acquisition Activity (USAMRAA) topic areas. DoD Phase I awards follow similar size limits to NIH, but Phase II bridge and Phase III transition funding can be substantially larger if the technology meets a published DoD need.

A well-structured business plan distinguishes between which funding track to pursue in which phase of development — and lays out the milestones (biofilm data, ISO certification, 510(k) filing, first LOI from an OEM partner) that each funding tranche is designed to achieve. Ask Avvale's consultants to build this roadmap for your specific technology.

Startup Costs: What an Antimicrobial Coatings Company Actually Requires

The range of startup costs in this niche is wider than in most medtech categories because the business model choice drives capital requirements more than scale does. A licensing-only play (develop the IP, outsource the coating application) can be built for $250,000–$600,000. A full-stack contract coating operation with its own clean-room and analytical lab requires $500,000–$3.5 million before reaching commercial throughput. The table below covers the full-stack contract coating model, which is the more common startup architecture.

US Cost Breakdown

• Coating application equipment (ultrasonic spray systems, dip-coating lines, or parylene deposition units): $80,000–$400,000. Sono-Tek ultrasonic systems for catheters run $90,000–$180,000 per unit; a dip-coating line for orthopaedic implants is $50,000–$150,000. Budget for at least two application systems to avoid single-point-of-failure downtime.
• Clean-room or ISO 7 facility fit-out: $50,000–$500,000 depending on whether you lease a shell space and fit it out or contract with a certified clean-room builder. Many early-stage companies lease existing ISO 7 space from a contract research organisation to defer this capital.
• Analytical and QC laboratory equipment (scanning electron microscope for coating thickness verification, ICP-MS for silver ion quantification, biofilm challenge chambers for ASTM E2562 testing): $40,000–$200,000. Some companies access SEM and ICP-MS through university core facilities rather than purchasing.
• Raw materials and active-agent initial inventory (silver nitrate, silver nanoparticle dispersions, chlorhexidine diacetate, PHMB, polymer matrix materials): $15,000–$80,000. Pricing is volume-sensitive; silver nanoparticle dispersions run $50–$300/gram at lab scale, dropping dramatically at kilogram quantities.
• Regulatory consultancy and 510(k) or UKCA filing: $30,000–$250,000. The FDA 510(k) user fee itself is $22,171 in 2025 (reduced to $5,543 for companies with under $100M in gross receipts). Regulatory consulting to prepare the submission package — including predicate search, risk analysis, biocompatibility testing strategy, and sterilisation validation — typically runs $30,000–$150,000 depending on complexity.
• ISO 13485:2016 Quality Management System implementation and third-party certification: $20,000–$60,000. Certification body fees (BSI, SGS, Bureau Veritas) for an initial audit run $10,000–$35,000; internal staff time and consultant-led QMS build adds the remainder.
• IP and patent filing (provisional US application plus PCT for international coverage): $15,000–$50,000. A provisional plus one PCT application through a specialist patent attorney in the chemical/biomedical space typically costs $18,000–$35,000 in attorney fees before national-phase entry costs.
• Working capital buffer (6 months of operating costs before first commercial batch revenue): $30,000–$150,000.

UK startup costs in sterling are broadly 80–85% of the USD figures above at current exchange rates, with the main difference being facility costs — laboratory space in Cambridge or Leeds is significantly less expensive than equivalent space in Boston or San Diego, giving UK-founded companies a meaningful early cost advantage before scaling.

The Licensing-Only Route: Lower Capital, Longer Revenue Runway

A pure-licensing model (develop the formulation in partnership with a university lab, file patents, and license to OEMs) requires minimal equipment capex but demands substantial IP investment. Typical all-in costs: $80,000–$150,000 for R&D materials and lab access, $25,000–$50,000 for provisional plus PCT filing, and $30,000–$100,000 for in-vitro biocompatibility and antimicrobial efficacy data sufficient to interest an OEM. The risk is a longer time to royalty income — typically 3–5 years from formulation to first commercial OEM deployment.

Equipment Checklist for a Contract Antimicrobial Coatings Operation

Investor due diligence on antimicrobial coatings startups consistently flags equipment specification as an area where founders underestimate both the initial capital requirement and the ongoing maintenance and qualification burden. The following list covers what a ISO 13485-compliant contract coating lab requires at minimum commercial scale.

Coating Application Equipment

• Ultrasonic spray coating system — Sono-Tek ExactaCoat or Sono-Tek Impact series. Used for uniform deposition of silver nanoparticle dispersions, heparin, or polymer/antimicrobial blends onto catheters, stents, and guidewires. Price range: $90,000–$180,000 per unit. Requires annual qualification per ISO 13485.
• Dip-coating tower with controlled withdrawal speed — For hydrophilic/antimicrobial combination coatings on elongated substrates. Manual units: $25,000–$60,000; automated multi-well systems: $80,000–$180,000.
• Parylene deposition system (CVD) — For conformal antimicrobial coatings on complex 3D implants. Parylene deposition units from Specialty Coating Systems (SCS) or PVA TePla run $120,000–$350,000. Only required if parylene-based antimicrobial formulations are in your portfolio.
• Plasma surface pre-treatment system — For substrate activation before coating adhesion. Typically $15,000–$45,000. Required for most polymer substrates to achieve bond strength specifications.

Quality Control and Analytical Equipment

• Scanning electron microscope (SEM) with EDX — For coating thickness verification, uniformity mapping, and elemental analysis of silver distribution. Entry-level tabletop SEM (Hitachi TM4000): $60,000–$90,000. Full-feature bench-top SEM: $120,000–$250,000.
• ICP-MS or ICP-OES — For quantifying silver ion release rates (critical for biocompatibility dossier under ISO 10993-17). University core facility access: $80–$150/sample. In-house instrument: $50,000–$150,000.
• Biofilm challenge incubators and flow cells — For ASTM E2562 (continuous flow biofilm CLABSI model) and ASTM E2180 (agar-embedded bacteria kill testing). Standalone testing rigs: $8,000–$25,000 plus consumables.
• Coating adhesion and durability test rig — Peel strength, cross-cut adhesion (ASTM D3359), and immersion testing apparatus. Custom fabrication or adapted from universal test machines: $10,000–$30,000.

Clean-Room Infrastructure

• ISO 7 clean-room (Class 10,000) — Minimum classification for coating application on sterile device substrates. HEPA filtered HVAC, gowning ante-room, pressure differential monitoring. Fit-out cost: $80,000–$300,000 for a 400 sq ft room, excluding shell-space rental.
• Particle counter and environmental monitoring system — Required for ISO 13485 environmental control records. $3,000–$8,000 for handheld; $15,000–$30,000 for fixed-point continuous monitoring.

Revenue Streams, Margin Ranges, and Unit Economics

The revenue structure of an antimicrobial coatings company depends almost entirely on which business model it operates. Three distinct structures exist; most companies begin in one and transition to another as IP matures.

Model 1: Contract Coating Services

Contract coaters charge OEMs a per-device or per-batch service fee for applying antimicrobial coatings to client-supplied substrates. Pricing typically runs $8–$85 per device depending on device size, coating type, and required analytical documentation per lot. The gross margin on contract coating services is typically 55–70% at commercial scale — active-agent costs are low ($1–$5 per device) and the main cost driver is clean-room facility overhead and QA staff, which are largely fixed.

Worked example: A Pittsburgh-based contract coater processing 12,000 urinary catheters per month at an average service fee of $18/catheter generates $216,000/month in gross revenue. Active-agent cost (chlorhexidine solution): $2.20/catheter. Processing and consumables: $3.80/catheter. Gross margin: 66.7%. Monthly fixed overhead (facility, QA manager, regulatory staff): $70,000. Monthly EBITDA: $76,200, equating to a 35% EBITDA margin. At 20,000 units/month the same fixed cost base pushes EBITDA margin above 50% — the business scales well once fixed costs are covered.

Model 2: Technology Licensing

Technology licensors collect upfront licence fees ($50,000–$500,000 per OEM partner depending on exclusivity terms and market scope) plus ongoing royalties of 3–8% on coated-device sales by the licensee. Royalties at the higher end of the range are justified by strong patent coverage and clear clinical superiority data. Microban International charges royalties in the 3–5% range on device sales by partners using its silver-ion antimicrobial platform. This model generates near-100% gross margin on royalty income — the only ongoing costs are patent maintenance, technical support, and regulatory filing maintenance.

Worked example: A licensing company with three OEM partners, each paying a $150,000 upfront fee and 5% royalties on $2.0 million in annual coated-device sales, generates $450,000 in upfront fees plus $300,000 in royalties in Year 1 — $750,000 total. In Year 3, if each partner doubles their coated-device volume, royalties alone reach $600,000 on zero additional sales effort. The risk: OEM licensing is slow to close (12–36 months per deal) and licensees can develop competing technology in-house once they have sufficient scale.

Model 3: Integrated Device Sales

Integrated manufacturers produce and sell the finished antimicrobial-coated device directly to hospitals, surgery centres, and distributors. Gross margin for finished antimicrobial devices is typically 50–65% at scale, reflecting the 30–60% price premium over uncoated equivalents that hospitals accept when evidence of infection reduction is strong. Covalon's antimicrobial IV catheter dressings and their SilverCoat catheters sell at a premium that Covalon publicly reports supports gross margins in the 55–65% range. The capital requirement is highest in this model — full device manufacturing and regulatory clearance, not just coating application.

GPO Pricing and Price Realisation Gap

A critical nuance for any business plan covering antimicrobial coated device sales: list price and realised transaction price diverge significantly in US healthcare. Group purchasing organisations (GPOs — Vizient, Premier, HealthTrust) negotiate volume rebates of 15–40% off catalogue price. Financial projections must model at realised ASP, not list price. A common planning error is building revenue projections on list price and discovering in Year 2 that hospital procurement is buying through a GPO contract at a 25% discount to list — which compresses unit margins substantially and delays breakeven.

Regulatory Pathway: FDA, UKCA, and EU MDR

Regulatory strategy is where most business plan analyses of antimicrobial coatings fall short. The pathway is not simply "get a 510(k)" — it depends on what the antimicrobial agent is, whether it is the principal mechanism of action (PMOA), and what risk class the base device is assigned. A plan that ignores these distinctions will produce a grossly wrong regulatory timeline and cost estimate.

United States: FDA Pathway

510(k) Premarket Notification (Class II devices): The majority of antimicrobial-coated catheters, guidewires, and external fixation pins are Class II devices cleared via 510(k). The applicant must demonstrate substantial equivalence to a legally marketed predicate — common predicates include Hydromer's heparin-benzalkonium chloride catheters and Surmodics' hydrophilic antimicrobial coatings. The 510(k) user fee in 2025 is $22,171; reduced to $5,543 for companies with under $100M gross receipts. The FDA review clock is 90 days after acceptance, but total time from submission preparation to clearance is typically 6–18 months depending on the complexity of the biocompatibility and efficacy data package.

Combination Product Classification (when antimicrobial agent is the PMOA): If the antimicrobial component is a drug (rifampin, minocycline, chlorhexidine) and its pharmacological action is what makes the device work, the FDA Office of Combination Products (OCP) will likely assign the product to CDER as lead centre under 21 CFR Part 3. This requires a drug-device combination approach — substantially more expensive and time-consuming, typically adding 12–24 months versus a straightforward 510(k) route. Most companies actively structure their formulation chemistry to achieve antimicrobial efficacy through physical/surface-active mechanisms (silver ions, surface charge, superhydrophobic texture) rather than drug elution, specifically to avoid CDER classification.

ISO 13485:2016 and 21 CFR Part 820 (QSR): All US-marketed medical devices must be manufactured under a Quality Management System compliant with 21 CFR Part 820 (or the equivalent FDA Quality System Regulation, now aligned with ISO 13485). ISO 13485 certification from a recognised certification body (BSI, SGS, Bureau Veritas) takes 6–18 months to implement and certify and costs $20,000–$60,000 in certification audit fees plus internal implementation.

United Kingdom: MHRA and UKCA

In Great Britain, antimicrobial coated medical devices require registration with the MHRA and the UKCA mark (or CE mark, accepted until 30 June 2030 under current transitional arrangements per GOV.UK MHRA guidance). Class IIb devices — which include most implantable antimicrobial-coated products — require a UK-approved Notified Body assessment before market entry. Notified Body fees run £5,000–£30,000 for Class IIb assessment, with assessment timelines of 12–24 months. MHRA device registration fees are £100–£500 per device family. Non-UK manufacturers must appoint a UK Responsible Person. The MHRA's proposed International Reliance process would allow companies with FDA 510(k) clearance to use that clearance to streamline UKCA recognition — a significant potential benefit for dual-market launches planned for 2027 onwards.

European Union: EU MDR 2017/745

EU MDR replaced the legacy MDD 93/42/EEC in May 2021. Antimicrobial coated Class IIa and IIb devices require Notified Body CE marking under MDR — the Notified Body landscape has contracted significantly since 2021, with only BSI, TÜV SÜD, SGS, and a handful of others maintaining full EU MDR designation. Wait times for Notified Body slots have extended to 12–18 months in some cases. Combination products where the antimicrobial agent functions as an ancillary medicinal substance also require EMA consultation, adding another 12 months and €50,000–€200,000 in additional costs. Budget accordingly if the EU is a priority market.

Canada: Health Canada Medical Devices Regulations (SOR/98-282)

Antimicrobial coated devices classified as Class III in Canada (most implantable antimicrobial-coated products) require a Medical Device Licence, a complete quality system audit, and a Canadian agent if the manufacturer is based outside Canada. The application fee for a Class III Medical Device Licence is CAD $5,000 (2025). Review timelines run 60–300 days depending on device complexity and whether the applicant uses a previously approved predicate or submits de novo.

Five Costly Mistakes in Antimicrobial Coatings Medical Device Businesses

Most of the business plan errors we see in this niche are not strategic — they are operational assumptions that looked plausible at the desk but fail on contact with the regulatory process or the hospital procurement system. These five mistakes account for the majority of preventable cost overruns and timeline slippage.

Mistake 1: Discovering the PMOA Question Late

The single most expensive mistake is selecting a drug-based antimicrobial agent (rifampin/minocycline combination, chlorhexidine at pharmacological dose levels) and only discovering in Year 2 of development that the FDA's Office of Combination Products will classify the product under CDER rather than CDRH. This reclassification typically adds 12–24 months to market entry and $200,000–$500,000 in additional regulatory work. The fix: request an OCP designation letter early (typically in the pre-submission meeting with FDA), and — wherever technically possible — formulate the coating to achieve antimicrobial efficacy through surface-active, physical, or ionic mechanisms rather than drug elution.

Mistake 2: Underestimating ISO 13485 Implementation Time

Founders routinely allocate 3–4 months for ISO 13485 implementation and certification. The actual timeline from starting QMS documentation to passing a third-party certification audit is 12–18 months for a new organisation with no existing quality infrastructure. Underestimating this timeline pushes back the 510(k) submission date (which requires documented manufacturing under the QMS) and delays commercial launch. Build at least 15 months of QMS implementation into the business plan timeline from Day 1.

Mistake 3: Pricing Contract Coating Services on Cost-Plus

Many founders price their contract coating services at cost-plus-margin, arriving at $8–$12/catheter. The correct pricing anchor is value-in-use at the hospital: a CLABSI costs $63,000 per case; an antimicrobial catheter that reduces CLABSI risk by 50% on a 1,000-catheter installation generates $315,000 in avoided costs per year. At $22/catheter instead of $12/catheter, the hospital still captures 96% of the value. Contracts with acute-care hospitals should be priced against infection cost avoidance, not against the uncoated device equivalent, and the financial model in the business plan should demonstrate this value-in-use calculation explicitly.

Mistake 4: Skipping Biofilm Challenge Testing Too Early

Companies that defer biofilm challenge testing (ASTM E2562, ISO 22196) until pre-submission discovery sometimes find that the coating formulation fails to maintain efficacy after sterilisation cycling or after 30-day immersion. Reformulation at the IDE or 510(k) stage adds 6–18 months to the timeline. The fix: run abbreviated ASTM E2562 biofilm challenge testing as early as proof-of-concept (Phase I), before investing in scale-up equipment, and build the full ISO 10993 biocompatibility battery alongside, not after, the efficacy dataset.

Mistake 5: Ignoring Antimicrobial Resistance Profiling

As of 2024–2025, hospital procurement committees and NHS AHSN networks increasingly require evidence that a proposed antimicrobial coating does not select for resistant strains through sub-MIC exposure. This requirement is not yet formalised in FDA or EU MDR guidance, but it has appeared in hospital tender specifications for antimicrobial device procurement in the UK, Germany, and the US Veterans Affairs network. Companies that have invested in minimum inhibitory concentration (MIC) shift testing and resistance profiling against MRSA, E. coli, and P. aeruginosa are winning tenders that companies with efficacy-only data are losing. Build resistance profiling into the clinical evidence package from Year 1.

Sample Business Plan Extract

What the Antimicrobial Coatings Medical Devices Business Plan Template Covers

The industry-specific template ($5) and the bespoke plan ($1,000/$800) follow the same structure, built around the sections investors, SBA lenders, and hospital procurement partners expect to see from a medtech company in this space.

• Executive Summary — Business model type (contractor / licensor / integrated device maker), funding ask, market position statement
• Company Overview — Legal structure, founding team, IP ownership, location rationale (proximity to OEM customers or hospital clusters)
• Market Analysis — Antimicrobial medical device coatings market size, HAI cost burden, device category breakdown (catheter vs. orthopaedic vs. surgical), competitive landscape (Hydromer, Surmodics, Covalon, Microban, Biocoat)
• Business Model Analysis — Detailed description of revenue model (service fees, licensing structure, or device sales), pricing strategy, GPO pricing dynamics, margin waterfall
• Technology and IP — Coating chemistry, active agents, application method, patent filing status, freedom-to-operate analysis summary
• Regulatory Strategy — Pathway (510(k), PMA, De Novo, combination product designation), timeline, PMOA analysis, ISO 13485 and QSR compliance plan
• Operations Plan — Facility requirements, equipment specification, clean-room qualification, QMS structure, supply chain for active agents
• Financial Projections — 5-year P&L, balance sheet, cash flow statement; per-device margin build; SBA 7(a) or SBIR drawdown schedule; breakeven analysis
• Funding Requirements — Capital required by phase, use-of-funds breakdown, investor terms or SBA application summary
• Exit Strategy — Acquisition scenarios (BD, Medtronic, Becton Dickinson have all acquired coating technology companies), IPO pathway, or licensing-only path to profitability

Related templates: 3D Printing Medical Devices Business Plan Template · Free Business Plan Templates Library · Work with a Business Plan Writer.

Glossary: Key Terms in Antimicrobial Coatings for Medical Devices

Business plans and investor decks in this niche frequently use technical terms without defining them, creating confusion for non-specialist readers on investment committees or at SBA offices. Defining these terms clearly in your plan demonstrates domain command.

Biofilm

A structured community of bacteria encased in a self-produced polymeric matrix, attached to a surface. Biofilm is the primary mechanism by which bacteria colonise indwelling medical devices such as catheters and orthopaedic implants, conferring antibiotic resistance 100–1,000x greater than planktonic (free-floating) cells.

Principal Mechanism of Action (PMOA)

The FDA's determination of which component of a combination product (drug, device, or biologic) is primarily responsible for the product's intended therapeutic effect. The PMOA determines which FDA centre leads the review (CDRH for devices, CDER for drugs).

PHMB (Polyhexamethylene Biguanide)

A broad-spectrum cationic polymer antimicrobial used in wound care, contact lens solutions, and surface antimicrobial coatings. PHMB disrupts bacterial cell membranes through electrostatic interaction. It is commonly paired with silver ions in antimicrobial catheter coatings for synergistic activity.

ISO 10993

A series of 20+ international standards governing the biological evaluation of medical devices. The series includes cytotoxicity (Part 5), sensitisation (Part 10), and chemical characterisation (Part 18), all required for any coated device submitted to the FDA or a Notified Body.

ASTM E2562

Standard test method for quantification of a Pseudomonas aeruginosa biofilm grown using a continuous tube reactor. The most commonly referenced biofilm quantification test in FDA submissions for antimicrobial catheter coatings.

GPO (Group Purchasing Organisation)

An entity that negotiates collective purchasing contracts on behalf of member hospitals. Vizient, Premier, and HealthTrust are the three largest US healthcare GPOs. GPO contract pricing typically runs 15–40% below catalogue list price, a discount that must be modelled explicitly in financial projections for device sales models.

510(k) Predicate

A legally marketed medical device to which a 510(k) applicant compares its device to demonstrate substantial equivalence. For antimicrobial-coated catheters, common predicates include Hydromer-coated heparin-benzalkonium chloride catheters and Surmodics hydrophilic/antimicrobial guidewire coatings cleared in prior 510(k)s.

Frequently Asked Questions

Avvale Business Plan Products

Template

Industry-Specific Template

Pre-filled antimicrobial coatings medical devices template with financial tables and regulatory notes.

$5 — Get Template

Instant download · Editable Word doc

Research + Content

Research & Content Pack

Full market research, competitor analysis, and written sections for your antimicrobial coatings plan.

$300 — Get Pack

Was $250 · Delivered in 3–5 days

Bespoke Plan

Fully Written Business Plan

Complete bespoke business plan written by Avvale consultants — investor, SBA, or bank-ready.

$1,000 — Get Plan

Was $800 · Turnaround 5–10 days